OR WAIT null SECS
The company's largest human study on BioCell Collagen II supports previous findings.
BioCell Technology LLC (Newport Beach, CA) has announced the completion of its largest human clinical study to date on BioCell Collagen II for joint health.
BioCell Collagen II is a hydrolyzed type II collagen ingredient containing chondroitin sulfate and hyaluronic acid.
The multi-center, double-blind, and placebo-controlled study assessed the ingredient’s safety as well as efficacy over long-term use in 80 patients with joint pain symptoms related to osteoarthritis.
“I am particularly excited about these findings because they confirm earlier studies and offer further support that BioCell Collagen II is a safe and effective alternative to prescription drug products,” said Joosang Park, PhD, vice president of scientific affairs at BioCell Technology. “Qualitative and quantitative outcomes from this study indicate improvement in pain, stiffness, mobility, and overall improvement in quality of life.”
Details of the study are expected to be available in the coming months.
In addition to the recently completed study, BioCell Technology has introduced a new topical format for the joint health ingredient: BioCell Collagen II CG-WS (cosmetic grade, water soluble).